CL2019003000A1 - Proteínas de unión a antígenos trem2 y usos de estas. - Google Patents

Proteínas de unión a antígenos trem2 y usos de estas.

Info

Publication number
CL2019003000A1
CL2019003000A1 CL2019003000A CL2019003000A CL2019003000A1 CL 2019003000 A1 CL2019003000 A1 CL 2019003000A1 CL 2019003000 A CL2019003000 A CL 2019003000A CL 2019003000 A CL2019003000 A CL 2019003000A CL 2019003000 A1 CL2019003000 A1 CL 2019003000A1
Authority
CL
Chile
Prior art keywords
binding proteins
trem2
antigen binding
myeloid
cells
Prior art date
Application number
CL2019003000A
Other languages
English (en)
Inventor
Ian Foltz
Shilpa Sambashivan
Irwin Chen
Susie Miki Harris
Warshaviak Dora Toledo
Ian Driver
Daniel Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019003000A1 publication Critical patent/CL2019003000A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A PROTEÍNAS DE UNIÓN A ANTÍGENOS, TALES COMO ANTICUERPOS MONOCLONALES, QUE SE UNEN ESPECÍFICAMENTE Y ACTIVAN EL RECEPTOR DE ACTIVACIÓN HUMANO EXPRESADO EN CÉLULAS MIELOIDES 2 (TREM2) Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHAS PROTEÍNAS DE UNIÓN A ANTÍGENOS. LAS PROTEÍNAS DE UNIÓN A ANTÍGENOS AGONISTAS (POR EJEMPLO, ANTICUERPOS) DE LA INVENCIÓN SON CAPACES DE ACTIVAR LA SEÑALIZACIÓN DE TREM2/DAP12 EN CÉLULAS MIELOIDES EN AUSENCIA DE RETICULACIÓN MEDIADA POR FC DE LAS PROTEÍNAS DE UNIÓN A ANTÍGENOS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA TRATAR O PREVENIR AFECCIONES ASOCIADAS A LA PÉRDIDA DE FUNCIÓN DE TREM2, TALES COMO LA ENFERMEDAD DE ALZHEIMER Y LA ESCLEROSIS MÚLTIPLE, MEDIANTE EL USO DE PROTEÍNAS DE UNIÓN A ANTÍGENOS.
CL2019003000A 2017-04-21 2019-10-18 Proteínas de unión a antígenos trem2 y usos de estas. CL2019003000A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488691P 2017-04-21 2017-04-21
US201762530753P 2017-07-10 2017-07-10
US201762580400P 2017-11-01 2017-11-01

Publications (1)

Publication Number Publication Date
CL2019003000A1 true CL2019003000A1 (es) 2020-02-14

Family

ID=63856168

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003000A CL2019003000A1 (es) 2017-04-21 2019-10-18 Proteínas de unión a antígenos trem2 y usos de estas.

Country Status (20)

Country Link
US (2) US11186636B2 (es)
EP (1) EP3612218A4 (es)
JP (2) JP7252134B2 (es)
KR (1) KR20200018778A (es)
CN (1) CN110709100A (es)
AU (2) AU2018254600B2 (es)
BR (1) BR112019021991A2 (es)
CA (1) CA3060409A1 (es)
CL (1) CL2019003000A1 (es)
CO (1) CO2019012998A2 (es)
CR (2) CR20210171A (es)
JO (1) JOP20190248A1 (es)
MA (1) MA52273A (es)
MX (2) MX2019012364A (es)
PE (1) PE20200485A1 (es)
PH (1) PH12019502356A1 (es)
SG (1) SG11201909646TA (es)
TW (2) TW202423975A (es)
UY (1) UY37698A (es)
WO (1) WO2018195506A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA2997960A1 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
TWI811229B (zh) * 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US20230132366A9 (en) 2018-11-26 2023-04-27 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3122725A1 (en) * 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
WO2020160468A1 (en) * 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
MX2021009722A (es) 2019-02-20 2021-09-14 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos.
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
EP4008351A4 (en) * 2019-08-02 2023-08-09 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. ANTI-PD-1 ANTIBODIES AND ASSOCIATED MEDICAL USE
CN115279790A (zh) 2020-01-13 2022-11-01 戴纳立制药公司 抗trem2抗体和其使用方法
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
EP4110814A1 (en) 2020-02-24 2023-01-04 Alector LLC Methods of use of anti-trem2 antibodies
IL296992A (en) 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
BR112023002093A2 (pt) * 2020-08-05 2023-04-25 Vigil Neuroscience Inc Tratamento de doenças relacionadas à disfunção do receptor do fator estimulador de colônias 1 usando agonistas de trem2
AU2021392813A1 (en) * 2020-12-04 2023-06-29 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
EP4405385A1 (en) * 2021-09-21 2024-07-31 Quell Therapeutics Limited Anti-trem2 chimeric antigen receptor
MX2024006208A (es) * 2021-11-22 2024-08-19 Vigil Neuroscience Inc Anticuerpo anti-trem2 y usos del mismo.
EP4448563A1 (en) 2021-12-17 2024-10-23 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
CN117964768B (zh) * 2024-04-02 2024-06-28 上海宏成药业有限公司 抗trem2抗体及其用途

Family Cites Families (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
WO1998039446A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
CA2431177C (en) 2000-12-08 2015-04-14 Baylor College Of Medicine Trem-1 splice variant for use in modifying immune responses
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
MXPA04003291A (es) 2001-10-12 2004-07-23 Schering Corp Uso de anticuerpos biespecificos para ragular respuestas inmunes.
US20060263770A1 (en) 2002-03-22 2006-11-23 Marco Colonna Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2489145A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Insulin-sensitizing agent
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
BRPI0511479C1 (pt) * 2004-05-27 2021-05-25 Crucell Holland Bv molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
KR20060135280A (ko) 2005-06-24 2006-12-29 전남대학교산학협력단 선천성 면역에 관여하는 트렘-2의 클로닝
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
CA2551163A1 (en) 2006-07-17 2008-01-17 Boehringer Ingelheim International Gmbh Methods for treating inflammatory, autoimmune or bone resorption diseases
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
MX2009007368A (es) 2007-01-16 2009-07-16 Wyeth Corp Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
RU2540150C2 (ru) 2007-06-25 2015-02-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами
GR1007327B (el) 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
WO2009036209A2 (en) 2007-09-14 2009-03-19 Amgen Inc. Homogeneous antibody populations
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
US20110256213A1 (en) 2008-10-15 2011-10-20 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
US20120183509A1 (en) 2009-04-28 2012-07-19 Harald Neumann Microglial precursor cells for the treatment of malignant neoplasms of the central nervous system
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
CN102038698A (zh) 2009-10-14 2011-05-04 山东绿叶天然药物研究开发有限公司 莫诺苷的新用途
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102127168A (zh) 2010-01-19 2011-07-20 中国人民解放军第二军医大学 一种髓样细胞表达激发受体-1的重组融合蛋白及其应用
KR20110086460A (ko) 2010-01-22 2011-07-28 한국교원대학교산학협력단 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
EP2555789B1 (en) 2010-04-08 2020-06-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
CN104402997A (zh) 2010-04-30 2015-03-11 阿雷克森制药公司 在人中具有降低的免疫原性的抗体
WO2012016333A1 (en) 2010-08-06 2012-02-09 University Health Network Biomarkers for malaria
US20130130354A1 (en) 2010-09-28 2013-05-23 CTI Salud S.A. Novel genes and uses thereof, expression profile of colon, gastric and pancreatic cancer
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US20140038285A1 (en) 2011-03-11 2014-02-06 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
KR20120112973A (ko) 2011-04-04 2012-10-12 전남대학교산학협력단 비만 또는 제 2형 당뇨의 예방 또는 치료용 조성물
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
BR112014009753B1 (pt) 2011-10-21 2020-09-15 Stemgenics, Inc Nanopartícula biocompatível funcionalizada e respectivo uso
MX358862B (es) 2011-11-04 2018-09-06 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI450727B (zh) 2011-12-29 2014-09-01 Ind Tech Res Inst 抗人類輸鐵蛋白受體的單域抗體與其應用
CN102517287B (zh) 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
KR20130114951A (ko) 2012-04-10 2013-10-21 한양대학교 산학협력단 폴리감마글루탐산을 포함하는 Ｔｈ17 매개성 질환 예방 또는 치료용 조성물
NZ705899A (en) 2012-09-07 2018-08-31 Inst Nat Sante Rech Med Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
MX370848B (es) * 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
CA2887825A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Engineered igg fc domains
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9066928B1 (en) 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CN105358578B (zh) 2013-05-20 2021-08-06 豪夫迈·罗氏有限公司 运铁蛋白受体的抗体及其使用方法
KR20150010326A (ko) 2013-07-19 2015-01-28 전남대학교산학협력단 비만 및 제 2형 당뇨 또는 지방간의 예방 또는 치료용 바이아릴아마이드를 포함한 유도체 화합물
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
KR101402921B1 (ko) 2013-08-28 2014-06-02 전남대학교산학협력단 비만 또는 제 2형 당뇨의 치료를 위한 레스베라톨 유도체의 이용
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
CN103555829B (zh) 2013-10-12 2015-10-21 厦门人瑞生物医药科技有限公司 一种检测trem2基因r47h突变的探针、试剂盒和方法
EP3092494A4 (en) 2014-01-06 2017-10-18 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN103866041A (zh) 2014-04-04 2014-06-18 厦门大学 帕金森病和脑白质疏松症的突变检测试剂盒及其检测方法
SI3129406T1 (sl) 2014-04-11 2019-04-30 Medimmune, Llc Konjugirane spojine, ki vsebujejo cisteinsko konstruirana protitelesa
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
ES2974575T3 (es) 2014-07-17 2024-06-27 Novo Nordisk As Mutagénesis dirigida al sitio de anticuerpos contra TREM-1 para disminuir la viscosidad
EP3177322A4 (en) * 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
KR101756417B1 (ko) 2014-08-21 2017-07-10 한국유나이티드제약 주식회사 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물
IL294043B2 (en) 2014-09-28 2024-10-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
US20170334977A1 (en) 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
JP2018516901A (ja) 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ アミロイドβのガランタミンクリアランス
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
KR20180033502A (ko) 2015-06-12 2018-04-03 알렉터 엘엘씨 항-cd33 항체 및 그의 사용 방법
US10765679B2 (en) 2015-07-04 2020-09-08 Emory University Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
MD3456346T2 (ro) 2015-07-30 2021-11-30 Macrogenics Inc Molecule de legare la PD-1 și LAG-3 și metode de utilizare a acestora
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
CA2997960A1 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3368575A2 (en) 2015-10-29 2018-09-05 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
EP3442543A4 (en) 2016-02-11 2020-01-22 The Johns Hopkins University COMPOSITIONS AND METHODS FOR NEUROGENESIS
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
EP3423493A2 (en) 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
US11944665B2 (en) 2016-06-01 2024-04-02 University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
EP3487886A2 (en) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Trem2 cleavage modulators and uses thereof
CN106244682B (zh) 2016-07-29 2019-11-26 中山大学 Trem-2基因在鉴别猪对蓝耳病毒易感性中的应用
CN106636330B (zh) 2016-09-21 2017-12-15 郁金泰 阿尔茨海默病的诊断和治疗药物
CA3040687A1 (en) 2016-10-14 2018-04-19 Childrens' Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
EP3551661A1 (en) 2016-12-09 2019-10-16 Alector LLC Anti-sirp-alpha antibodies and methods of use thereof
JP2020515813A (ja) 2016-12-23 2020-05-28 ジェナボン バイオファーマシューティカルズ エルエルシー アルツハイマー病の診断および治療においてｇｍ６を使用する方法
EP3568020A4 (en) 2017-01-12 2020-11-11 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINIZING CONDITIONS
WO2018134815A2 (en) 2017-01-17 2018-07-26 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US20210293794A1 (en) 2017-02-24 2021-09-23 University Of Hawii Cancer Center Metabolic biomarkers for the identification and characterization of alzheimers disease
JP2020513794A (ja) 2017-02-28 2020-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多能性幹細胞および造血始原細胞からのヒトミクログリア様細胞の分化と使用
WO2018175581A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
KR101936249B1 (ko) 2017-04-04 2019-01-08 경희대학교 산학협력단 쿠마타케닌을 포함하는 암의 예방, 개선 또는 치료용 조성물
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20180318379A1 (en) 2017-05-01 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
US20180340945A1 (en) 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
JP2020522266A (ja) 2017-06-05 2020-07-30 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２−ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
EP3645050A4 (en) 2017-06-25 2021-08-11 Systimmune, Inc. MULTI-SPECIFIC ANTIBODIES AND ASSOCIATED PRODUCTION AND USE PROCESSES
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
CN109206503A (zh) 2017-07-07 2019-01-15 厦门大学 一种蛋白用于制备防治阿尔茨海默病药物的用途
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
CA3067509A1 (en) 2017-07-27 2019-01-31 Novartis Ag Sheddase resistant trem2 variants
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
CN110662765B (zh) 2017-08-03 2023-09-29 艾利妥 抗cd33抗体及其使用方法
JP7267280B2 (ja) 2017-08-08 2023-05-01 パイオニア イミュノセラピューティクス インコーポレイテッド Ｔｒｅｍ１を発現する骨髄細胞を無能化させるための組成物および方法
EP3681909A1 (en) 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US20200309788A1 (en) 2017-09-29 2020-10-01 The General Hospital Corporation Methods for identifying and treating adrenomyeloneuropathy (amn)
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMIAL DISORDERS
WO2019079529A1 (en) 2017-10-17 2019-04-25 The Translational Genomics Research Institute TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
US10597462B1 (en) 2017-11-08 2020-03-24 University Of Puerto Rico Anti-TLT-1 antibody and uses thereof
CN111556761A (zh) 2017-11-15 2020-08-18 拉瓦尔大学 Srsf3药剂用于治疗和/或预防神经病症、癌症、细菌感染或病毒感染的用途
CN109837330A (zh) 2017-11-28 2019-06-04 上海中优精准医疗科技股份有限公司 一种检测trem2基因多态性的探针及方法
SG11202005484VA (en) 2017-12-12 2020-07-29 Pionyr Immunotherapeutics Inc Anti-trem2 antibodies and related methods
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体及びその使用方法
WO2019161080A1 (en) 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019180224A1 (en) 2018-03-22 2019-09-26 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
TWI839050B (zh) 2018-04-02 2024-04-11 美商必治妥美雅史谷比公司 抗trem-1抗體及其用途
EP3773543A4 (en) 2018-04-09 2022-04-06 The General Hospital Corporation COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS
KR20210015872A (ko) 2018-05-25 2021-02-10 알렉터 엘엘씨 항-sirpa 항체 및 그의 사용 방법
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
CN108752482B (zh) 2018-06-12 2019-04-30 南京卡提医学科技有限公司 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用
EP3809838A4 (en) 2018-06-21 2022-03-23 The Jackson Laboratory GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
KR20210025614A (ko) 2018-06-29 2021-03-09 알렉터 엘엘씨 항-sirp-베타1 항체 및 그의 사용 방법
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
CA3106038A1 (en) 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US20210311076A1 (en) 2018-07-16 2021-10-07 University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases
CN109112214A (zh) 2018-07-27 2019-01-01 复旦大学附属中山医院 模式识别受体trem2在肝癌预后和治疗中的应用
EP3830123A1 (en) 2018-07-27 2021-06-09 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
KR20210071974A (ko) 2018-09-05 2021-06-16 더 제너럴 하스피탈 코포레이션 사이토카인 방출 증후군을 치료하는 방법
BR112021004316A2 (pt) 2018-09-11 2021-11-03 Washington University St Louis Anticorpos de agonistas anti-trem-2
WO2020056114A1 (en) 2018-09-12 2020-03-19 Board Of Regents Of The University Of Nebraska Antimicrobial compositions and methods
US20210364532A1 (en) 2018-09-28 2021-11-25 Inotrem Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy
KR102096282B1 (ko) 2018-10-15 2020-04-02 재단법인대구경북과학기술원 재조합 베큘로바이러스를 이용한 인간 ｔｒｅｍ２ 세포막 단백질의 효율적인 정제방법
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN111135185A (zh) 2018-11-02 2020-05-12 杭州星鳌生物科技有限公司 天然免疫激活通过调控髓系细胞触发受体trem2抑制大脑神经慢性炎症
US20220127373A1 (en) 2018-11-08 2022-04-28 The Regents Of The University Of California Systems and methods for targeting cancer cells
US20230132366A9 (en) 2018-11-26 2023-04-27 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
US20220089768A1 (en) 2019-01-04 2022-03-24 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
CN109646668B (zh) 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
WO2020150214A1 (en) 2019-01-14 2020-07-23 University Of Virginia Patent Foundation Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury
US20220104468A1 (en) 2019-01-22 2022-04-07 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
WO2020154348A1 (en) 2019-01-23 2020-07-30 The Regents Of The University Of California Human genomic construct reporter cells and mouse models to screen therapeutics against microglia-expressed disease associated genes
WO2020160468A1 (en) 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
CN113508178A (zh) 2019-02-01 2021-10-15 西雅图儿童医院（Dba西雅图儿童研究所） 用于调节经工程化的基因的表达的微环境传感器
WO2020160441A1 (en) 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
MX2021009722A (es) 2019-02-20 2021-09-14 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos.
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CN110320368A (zh) 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
CN110241208A (zh) 2019-08-02 2019-09-17 辽宁中医药大学 Trem2作为早期诊断冠心病的分子标志物的应用
CN110511240B (zh) 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
CN110882262A (zh) 2019-11-06 2020-03-17 南京医科大学 一种髓细胞触发受体2的激活用药及其应用
BR112022007944A2 (pt) 2019-11-22 2022-07-12 Lilly Co Eli Anticorpos trem2 e usos dos mesmos
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
CN111184742B (zh) 2020-02-13 2022-06-24 中山大学附属第五医院 Trem-2+t细胞在制备用于治疗结核病药物中的应用

Also Published As

Publication number Publication date
TW202423975A (zh) 2024-06-16
US20210054069A1 (en) 2021-02-25
PE20200485A1 (es) 2020-03-03
AU2022221560A1 (en) 2022-09-22
CR20210171A (es) 2021-05-21
CO2019012998A2 (es) 2020-02-18
AU2018254600A1 (en) 2019-10-24
KR20200018778A (ko) 2020-02-20
BR112019021991A2 (pt) 2020-06-16
CR20190525A (es) 2020-03-20
CN110709100A (zh) 2020-01-17
TWI812619B (zh) 2023-08-21
MX2024000156A (es) 2024-01-23
JOP20190248A1 (ar) 2019-10-20
PH12019502356A1 (en) 2020-12-07
JP2020517249A (ja) 2020-06-18
JP7559025B2 (ja) 2024-10-01
JP7252134B2 (ja) 2023-04-04
CA3060409A1 (en) 2018-10-25
SG11201909646TA (en) 2019-11-28
EP3612218A1 (en) 2020-02-26
WO2018195506A1 (en) 2018-10-25
US20220204611A1 (en) 2022-06-30
AU2018254600B2 (en) 2022-05-26
MA52273A (fr) 2021-04-28
UY37698A (es) 2018-10-31
US11186636B2 (en) 2021-11-30
EP3612218A4 (en) 2021-07-28
MX2019012364A (es) 2019-11-28
TW201906628A (zh) 2019-02-16
JP2022188272A (ja) 2022-12-20

Similar Documents

Publication Publication Date Title
CL2019003000A1 (es) Proteínas de unión a antígenos trem2 y usos de estas.
CL2022003769A1 (es) Anticuerpos de unión a cd3
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
MY194669A (en) Binding Proteins and Methods of use Thereof
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
PE20212132A1 (es) Agentes de union a c3 y metodos para su uso
MX2021005085A (es) Formulacion de anticuerpo.
EA201992883A1 (ru) АНТИТЕЛА К TrkB
AR112770A1 (es) Anticuerpos anti-ctla-4 y sus usos
AR111914A1 (es) Proteínas de unión a antígenos trem2 y usos de estas